SynthesisDermatologic therapy2021
Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review.
Synthesis in Dermatologic therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Health-related Quality of Life Measurements in Patients with Actinic Keratosis: A Systematic Review.Acta dermato-venereologica · 2026Pooled it
- Spontaneous regression rates of actinic keratosis: a systematic review and pooled analysis of randomized controlled trials.Scientific reports · 2022Pooled it
- Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review.Dermatologic therapy · 2021Pooled it
- Clinical Clearance of Actinic Keratoses with Tirbanibulin 1% Ointment: Evidence from a Meta-Analysis.Life (Basel, Switzerland) · 2026Article
- Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel.JAAD international · 2024Article
- Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment.Dermatology practical & conceptual · 2024Review
- Advancements in elucidating the pathogenesis of actinic keratosis: present state and future prospects.Frontiers in medicine · 2024Review
- Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis: The Personalizing Actinic Keratosis Treatment (PAKT) Project.Acta dermato-venereologica · 2023Article
- Reasons for Patient Call-backs while being Treated with Topical 5-fluorouracil: A Retrospective Chart Review.The Journal of clinical and aesthetic dermatology · 2023Article
- Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis.JMIR dermatology · 2023Article
- Fully home-based methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face or scalp: A real life open study.Dermatologic therapy · 2022Article
- Clinical Characteristics of Actinic Keratosis Associated with the Risk of Progression to Invasive Squamous Cell Carcinoma: A Systematic Review.Journal of clinical medicine · 2022Review
- Article
- Profile of Tirbanibulin for the Treatment of Actinic Keratosis.The Journal of clinical and aesthetic dermatology · 2022Article
- Actinic Keratoses (AK): An Exploratory Questionnaire-Based Study of Patients' Illness Perceptions.Current oncology (Toronto, Ont.) · 2022Article
- 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses.The Annals of pharmacotherapy · 2022Review
- Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action.Clinical, cosmetic and investigational dermatology · 2022Review
- Treatment Options and Post-Treatment Malignant Transformation Rate of Actinic Cheilitis: A Systematic Review.Cancers · 2021Review
- Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients' perspectives on actinic keratosis treatments may have an impact on treatment adherence and, therefore, therapeutic outcomes. We performed a systematic review to assess patients' perspectives of topical, field-directed treatments for actinic keratoses. A literature search was conducted, and 14 studies were identified encompassing 4433 patients. Only four studies were focused on face and/or scalp, which are the locations that typically impact patients' quality of life. Four studies were clinical trials. One study utilized a validated patient-reported outcomes (PRO) instrument specifically developed for actinic keratosis. In general, treatment adherence and patient satisfaction were better with shorter-duration treatment regimens such as ingenol mebutate gel. Imiquimod improved quality of life in one study but not in another. No data was available on topical piroxicam. The findings underscore the need for effective and well-tolerated, short-duration topical treatment for actinic keratosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.